60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments

Abstract

Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic disease in young adults. While approximate values of the disease burden of MS are known, individual drivers are unknown. Objective: To estimate the age-, sex-, and disease severity-specific contributions to the disease burden of MS. Methods: We estimated the disease burden of MS using disability-adjusted life years (DALYs) following the Global Burden of Disease study (GBD) methodology. The data sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the Swiss mortality registry. Conclusions: Morbidity has a larger influence on the disease burden of MS than mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild and moderate/severe disease stage in Switzerland. Interventions to reduce severity worsening in combination with tailored, symptomatic treatments are important future paths to lower the disease burden of MS.

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

“…This is consistent with a DALY-based estimate of disease burden in Swiss MS patients, in which patients with an EDSS score <4 (68.4% of the total MS population) contributed only 39.8% to the total MS-specific YLD. 30 The estimated number of relapses and the relapse-related costs in the model were lower in the immediate OMB and early switch cohorts than in the late and no switch cohorts. As two thirds of relapse costs can be attributed to indirect costs, 31 relapse-related absenteeism, early retirement and invalidity also need consideration.…”

“…This is consistent with a DALY-based estimate of disease burden in Swiss MS patients, in which patients with an EDSS score <4 (68.4% of the total MS population) contributed only 39.8% to the total MS-specific YLD. 30 …”

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

“…Dies geht aus einer DALY-basierten Schätzung der Krankheitslast bei Schweizer Patienten hervor. Dort trugen Patienten mit einem EDSS-Score von < 4 (68,4 % der gesamten Population) nur 39,8 % zur gesamten MS-spezifischen YLD bei 22 .…”

First Insights into Barriers and Facilitators from the Perspective of Persons with Multiple Sclerosis: A Multiple Case Study

“…Almost 70% of persons with MS are women [ 1 ]. In 2020, nearly 15,000 persons with MS (PwMS) lived in Switzerland [ 2 ]. This amounts to 180 affected people per 100.000 of the population.…”